Tonix Pharmaceuticals Presents Data on High Economic Burden of Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals presented real-world data at ISPOR 2026 showing that over 93% of fibromyalgia patients have comorbidities and incur substantial healthcare costs, highlighting the unmet need for effective treatments as the company prepares to launch TONMYA.
